C-GXDCpeptidomimetics, broad-spectrum anti-infectives, innate immunity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop biostable, low molecular weight peptidomimetic compounds that mimic innate immune peptides and target viruses, bacteria, fungi, and biofilms.
Peptidomimetic anti-infective discovery platform based on innate immune peptide mimicry.
Platform supports Maxwell's preclinical anti-infective pipeline.
Company states the platform targets viruses, bacteria, fungi, and biofilm formations.
Develop a broad-spectrum anti-infective drug candidate targeting viral, bacterial, fungal, and biofilm-related pathogens.
CLAROMER peptidomimetic anti-infective compound.
Human trials are planned for 2026.
Company states MXB-22,510 has shown broad preclinical activity.
Develop a nasal spray product within Maxwell's anti-infective pipeline.
Nasal spray formulation; specific active compound and indication are not disclosed in the supplied material.
Listed on Maxwell's pipeline.
Develop an oral product within Maxwell's anti-infective pipeline.
Oral formulation; specific active compound and indication are not disclosed in the supplied material.
Listed on Maxwell's pipeline.